Developer docs
API playgroundTry for free, no card

Search company profiles

Resolution Bioscience

Full company profile

uuid000aluz

Namestring
Resolution Bioscience
Websiteurl
resolutionbio.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Resolution Bioscience is a Kirkland, Washington-based healthcare research company founded in 2012 that specialized in next-generation sequencing (NGS) technology, molecular biology, and cancer diagnostics. The company's core offering is the ctDx FIRST Liquid Biopsy Platform, a proprietary technology that analyzes circulating tumor DNA (ctDNA) to enable non-invasive cancer detection and monitoring for precision oncology applications. The platform supports pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments, addressing the industry's need for diagnostic-drug co-development and personalized medicine requirements.

The company operated with 51-100 employees under a horizontal segmentation approach, targeting pharmaceutical firms as its primary customer segment. Resolution Bioscience's revenue mechanics centered on companion diagnostic partnerships with pharma, though specific pricing, contract values, or revenue figures were not publicly disclosed. Its value proposition rested on the ctDx FIRST platform's ability to detect genomic alterations guiding treatment decisions through a non-invasive liquid biopsy workflow, with the proprietary technology cited as a strong competitive differentiator.

In September 2023, Resolution Bioscience was acquired by Exact Sciences Corporation (now rebranded under Abbott), integrating the ctDx FIRST platform into Exact Sciences' broader precision oncology portfolio alongside products such as Cologuard, Oncodetect, Oncotype DX, and Cancerguard. Post-acquisition, Resolution Bioscience operates as a wholly-owned subsidiary, with its liquid biopsy technology now distributed through Exact Sciences' established laboratory testing infrastructure, healthcare provider networks, and international footprint spanning the US, UK, Germany, France, Italy, Japan, and Poland. Mark Li serves as President and CEO.

Short descriptiontext

Resolution Bioscience is a Kirkland, Washington-based healthcare company that developed the proprietary ctDx FIRST liquid biopsy platform for non-invasive cancer detection via circulating tumor DNA analysis, serving pharmaceutical companies with companion diagnostics for precision oncology drug development.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKirkland, United States
HQ citystring
Kirkland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
liquid biopsy diagnostics, circulating tumor DNA, companion diagnostics, precision oncology, NGS cancer testing
Industry5 codes
1Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
CodeHLAAANAGPrimaryYes
2Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
CodeHLAAAMAHPrimaryNo
3Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
CodeHLAAALAEPrimaryNo
4Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
CodeHLAAAMABPrimaryNo
5Companion Diagnostics (CDx) & Therapy Selection Assays
CodeHLAAALAFPrimaryNo
NAICS code4 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ctDx FIRST
Description

Liquid biopsy platform for precision oncology diagnostics

openpr.com
Core offering1 text field

Resolution Bioscience develops and offers the ctDx FIRST Liquid Biopsy Platform, a proprietary NGS-based diagnostic platform that analyzes circulating tumor DNA (ctDNA) for non-invasive cancer detection, monitoring, and treatment guidance. The platform serves pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Resolution Bioscience offered a focused product portfolio centered on its core ctDx FIRST liquid biopsy platform for precision oncology. The company was acquired by Exact Sciences in September 2023, integrating its liquid biopsy technology into Exact Sciences' broader cancer diagnostics offerings.

Product and service1 record
1ctDx FIRST Liquid Biopsy Platform
CategoryCancer Diagnostics / Liquid Biopsy
Description

A proprietary NGS-based liquid biopsy platform that analyzes circulating tumor DNA (ctDNA) to support non-invasive cancer detection, monitoring, and precision oncology treatment guidance. Used by pharmaceutical companies for companion diagnostic development and by clinicians to identify genomic alterations that inform targeted therapy selection.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Personalis
TypeDirect peer
Description

Personalis provides NeXT Personal, a tumor-informed liquid biopsy assay for MRD and recurrence monitoring, as well as ImmunoID Next for immuno-oncology. It competes directly with Resolution Bio's ctDNA-based oncology platform.

2NeoGenomics
TypeBroad incumbent
Description

NeoGenomics is a broader oncology diagnostics services company that operates liquid biopsy offerings including the RaDaR MRD assay (acquired via Inivata). It overlaps with Resolution Bio in oncology liquid biopsy and pharma CDx services, though with a much wider test menu.

3Foundation Medicine
TypeDirect peer
Description

Foundation Medicine's FoundationOne Liquid CDx is a directly competing FDA-approved liquid biopsy assay used for therapy selection in advanced cancer. Both companies serve biopharma CDx co-development and offer ctDNA-based therapy guidance assays.

4Burning Rock Biotech
TypeRegional player
Description

Burning Rock is a China-based liquid biopsy and NGS oncology diagnostics company offering ctDNA assays for therapy selection and MRD. It is a regional peer with comparable technology to Resolution Bio's ctDx FIRST but operates primarily in the Chinese market.

5Tempus Labs
TypeDirect peer
Description

Tempus offers the xT and xF liquid biopsy assays for oncology genomic profiling and biopharma CDx partnerships. It directly competes in NGS-based ctDNA testing and pharma companion diagnostic services.

6Exact Sciences
TypeBroad incumbent
Description

Exact Sciences (now Abbott) is the parent company of Resolution Bioscience and operates Oncodetect, OncoExTra, and Cancerguard liquid biopsy tests. As the acquirer of Resolution Bio, it is the most important strategic incumbent shaping the subsidiary's go-forward trajectory.

7Adaptive Biotechnologies
TypeEmerging player
Description

Adaptive Biotechnologies provides clonoSEQ for MRD monitoring in blood cancers and immune profiling services. While focused on hematologic malignancies, it competes for pharma CDx partnerships and oncology diagnostic spend overlapping with Resolution Bio's market.

8Natera
TypeDirect peer
Description

Natera's Signatera tumor-informed MRD assay is a ctDNA-based liquid biopsy test used for cancer recurrence monitoring and treatment response assessment. It competes directly with Resolution Bio's MRD-adjacent liquid biopsy positioning.

9Guardant Health
TypeDirect peer
Description

Guardant Health is a leading liquid biopsy company whose Guardant360 CDx is the dominant FDA-approved ctDNA assay for comprehensive genomic profiling. It directly competes with Resolution Bio's ctDx FIRST in oncology liquid biopsy and pharma CDx partnerships.

10Caris Life Sciences
TypeDirect peer
Description

Caris offers MI Profile and Caris Assure for molecular profiling and liquid biopsy, serving oncologists and biopharma for therapy selection and CDx development — directly overlapping Resolution Bio's customer base and use cases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resolution Bioscience

Cancer Diagnosticsresolutionbio.com

Resolution Bioscience is a Kirkland, Washington-based healthcare company that developed the proprietary ctDx FIRST liquid biopsy platform for non-invasive cancer detection via circulating tumor DNA analysis, serving pharmaceutical companies with companion diagnostics for precision oncology drug development.

What Resolution Bioscience does

Resolution Bioscience is a Kirkland, Washington-based healthcare research company founded in 2012 that specialized in next-generation sequencing (NGS) technology, molecular biology, and cancer diagnostics. The company's core offering is the ctDx FIRST Liquid Biopsy Platform, a proprietary technology that analyzes circulating tumor DNA (ctDNA) to enable non-invasive cancer detection and monitoring for precision oncology applications. The platform supports pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments, addressing the industry's need for diagnostic-drug co-development and personalized medicine requirements.

The company operated with 51-100 employees under a horizontal segmentation approach, targeting pharmaceutical firms as its primary customer segment. Resolution Bioscience's revenue mechanics centered on companion diagnostic partnerships with pharma, though specific pricing, contract values, or revenue figures were not publicly disclosed. Its value proposition rested on the ctDx FIRST platform's ability to detect genomic alterations guiding treatment decisions through a non-invasive liquid biopsy workflow, with the proprietary technology cited as a strong competitive differentiator.

In September 2023, Resolution Bioscience was acquired by Exact Sciences Corporation (now rebranded under Abbott), integrating the ctDx FIRST platform into Exact Sciences' broader precision oncology portfolio alongside products such as Cologuard, Oncodetect, Oncotype DX, and Cancerguard. Post-acquisition, Resolution Bioscience operates as a wholly-owned subsidiary, with its liquid biopsy technology now distributed through Exact Sciences' established laboratory testing infrastructure, healthcare provider networks, and international footprint spanning the US, UK, Germany, France, Italy, Japan, and Poland. Mark Li serves as President and CEO.

Resolution Bioscience firmographics

Firmographics
Name
Resolution Bioscience
Website
https://resolutionbio.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
Resolution Bioscience is a Kirkland, Washington-based healthcare company that developed the proprietary ctDx FIRST liquid biopsy platform for non-invasive cancer detection via circulating tumor DNA analysis, serving pharmaceutical companies with companion diagnostics for precision oncology drug development.
Ownership category
akta.pro rank

Resolution Bioscience industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
akta.pro secondary industries
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

Keywords

  • Liquid biopsy diagnostics
  • Circulating tumor DNA
  • Companion diagnostics
  • Precision oncology
  • NGS cancer testing

Where Resolution Bioscience is headquartered

Location

Headquarters

HQ city
Kirkland
HQ country
United States
HQ region
North America

Markets served

Resolution Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Resolution Bioscience product offering

Product offering

Core offering

Resolution Bioscience develops and offers the ctDx FIRST Liquid Biopsy Platform, a proprietary NGS-based diagnostic platform that analyzes circulating tumor DNA (ctDNA) for non-invasive cancer detection, monitoring, and treatment guidance. The platform serves pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments.

Product overview

Resolution Bioscience offered a focused product portfolio centered on its core ctDx FIRST liquid biopsy platform for precision oncology. The company was acquired by Exact Sciences in September 2023, integrating its liquid biopsy technology into Exact Sciences' broader cancer diagnostics offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • ctDx FIRST: Liquid biopsy platform for precision oncology diagnostics

Products and services

  • ctDx FIRST Liquid Biopsy Platform A proprietary NGS-based liquid biopsy platform that analyzes circulating tumor DNA (ctDNA) to support non-invasive cancer detection, monitoring, and precision oncology treatment guidance. Used by pharmaceutical companies for companion diagnostic development and by clinicians to identify genomic alterations that inform targeted therapy selection.

Companies that use Resolution Bioscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Resolution Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Resolution Bioscience partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Resolution Bioscience competitors and assessment

Company assessment

Direct peers

  • Personalis: Personalis provides NeXT Personal, a tumor-informed liquid biopsy assay for MRD and recurrence monitoring, as well as ImmunoID Next for immuno-oncology. It competes directly with Resolution Bio's ctDNA-based oncology platform.
  • Foundation Medicine: Foundation Medicine's FoundationOne Liquid CDx is a directly competing FDA-approved liquid biopsy assay used for therapy selection in advanced cancer. Both companies serve biopharma CDx co-development and offer ctDNA-based therapy guidance assays.
  • Tempus Labs: Tempus offers the xT and xF liquid biopsy assays for oncology genomic profiling and biopharma CDx partnerships. It directly competes in NGS-based ctDNA testing and pharma companion diagnostic services.
  • Natera: Natera's Signatera tumor-informed MRD assay is a ctDNA-based liquid biopsy test used for cancer recurrence monitoring and treatment response assessment. It competes directly with Resolution Bio's MRD-adjacent liquid biopsy positioning.
  • Guardant Health: Guardant Health is a leading liquid biopsy company whose Guardant360 CDx is the dominant FDA-approved ctDNA assay for comprehensive genomic profiling. It directly competes with Resolution Bio's ctDx FIRST in oncology liquid biopsy and pharma CDx partnerships.
  • Caris Life Sciences: Caris offers MI Profile and Caris Assure for molecular profiling and liquid biopsy, serving oncologists and biopharma for therapy selection and CDx development — directly overlapping Resolution Bio's customer base and use cases.

Broad incumbents

  • NeoGenomics: NeoGenomics is a broader oncology diagnostics services company that operates liquid biopsy offerings including the RaDaR MRD assay (acquired via Inivata). It overlaps with Resolution Bio in oncology liquid biopsy and pharma CDx services, though with a much wider test menu.
  • Exact Sciences: Exact Sciences (now Abbott) is the parent company of Resolution Bioscience and operates Oncodetect, OncoExTra, and Cancerguard liquid biopsy tests. As the acquirer of Resolution Bio, it is the most important strategic incumbent shaping the subsidiary's go-forward trajectory.

Regional players

  • Burning Rock Biotech: Burning Rock is a China-based liquid biopsy and NGS oncology diagnostics company offering ctDNA assays for therapy selection and MRD. It is a regional peer with comparable technology to Resolution Bio's ctDx FIRST but operates primarily in the Chinese market.

Emerging players

  • Adaptive Biotechnologies: Adaptive Biotechnologies provides clonoSEQ for MRD monitoring in blood cancers and immune profiling services. While focused on hematologic malignancies, it competes for pharma CDx partnerships and oncology diagnostic spend overlapping with Resolution Bio's market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Resolution Bioscience social profiles

Digital presence

Resolution Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resolution Bioscience leadership team

Management profile

Number of profiles

Resolution Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resolution Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resolution Bioscience

What does Resolution Bioscience do?

Resolution Bioscience develops and offers the ctDx FIRST Liquid Biopsy Platform, a proprietary NGS-based diagnostic platform that analyzes circulating tumor DNA (ctDNA) for non-invasive cancer detection, monitoring, and treatment guidance. The platform serves pharmaceutical companies developing targeted cancer therapies by providing companion diagnostic capabilities to identify patients likely to respond to specific treatments.

Is Resolution Bioscience a public or private company?

Resolution Bioscience is a private company. It is classified as corporate owned and is currently acquired.

When was Resolution Bioscience founded?

Resolution Bioscience was founded in 2012. It employs 51 to 100 people.

Where is Resolution Bioscience based?

Resolution Bioscience is headquartered in Kirkland, United States, in the North America region.

Who are Resolution Bioscience's main competitors?

Direct peers on record are Personalis, Foundation Medicine, Tempus Labs, Natera, Guardant Health and Caris Life Sciences. Broad incumbents are NeoGenomics and Exact Sciences. Burning Rock Biotech is listed as a regional player. Adaptive Biotechnologies is listed as an emerging player.

Does Resolution Bioscience have an API?

No public API is recorded for Resolution Bioscience.

What industry is Resolution Bioscience in?

Resolution Bioscience's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Segments and Major Growth Areas in the Companion Diagnostics MarketThe global companion diagnostics market is projected to reach $22.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.1% during the forecast period, driven by rising demand for personalized treatment options and increased precision medicine investments. In September 2023, Exact Sciences acquired Resolution Bioscience to incorporate its ctDx FIRST liquid biopsy platform, enhancing Exact Sciences' precision oncology offerings. In January 2024, Agilent Technologies entered into a partnership with pharmaceutical firm Incyte to develop companion diagnostics for hematology and oncology indications, combining Agilent's diagnostic expertise with Incyte's therapeutic portfolio.GenengnewsAgilent to Acquire Resolution Bioscience for up to $695M, Expanding in Precision MedicineAgilent Technologies has agreed to acquire Resolution Bioscience for up to $695 million to expand its presence in the precision medicine sector. This transaction represents a strategic move by Agilent to enhance its capabilities in targeted diagnostics and personalized healthcare solutions.PR NewswireGlobal Metagenomics Markets, 2022-2030: Emergence of New Fields in Genomics that Complement Metagenomics & Developments in Biotechnology & Bioinformatics TechniquesResearchAndMarkets published a global metagenomics market report projecting the market to reach USD 4.87 billion by 2030, growing at a CAGR of 14.4% from 2022 to 2030, driven by increasing genomics research, personalized medicine adoption, and demand for biologic products. Key industry developments cited include Illumina's expansion of genomics operations in Brazil (August 2022), Agilent Technologies' acquisition of Resolution Bioscience (April 2021), and a strategic partnership between Oxford University and Oracle to develop a cloud-based genomic sequencing platform for COVID-19 tracking. Market barriers include the high overall cost of metagenomics and limited accessibility to computation and analytic tools.PR NewswireCompanion Diagnostics Global Market Report 2022: Widespread Adoption of AI Presents OpportunitiesThe global companion diagnostics market is expected to grow from $4.37 billion in 2021 to $5.15 billion in 2022 and reach $9.99 billion in 2026, according to a market report, driven by increasing adoption of targeted cancer therapies and AI-driven technological advancements in diagnostics development. The market's growth is attributed to the rising number of genome-targeted therapies, with eligibility estimates increasing from 8.82% in 2018 to 13.60% in 2020. In April 2021, Agilent Technologies Inc. acquired Resolution Bioscience for $695 million to expand its NGS-based cancer diagnostics capabilities and meet demands in the precision medicine sector.PR NewswireGlobal Polymerase Chain Reaction Market to Surpass US$ 11,142.2 Million by 2030 - Coherent Market InsightsCoherent Market Insights projects the global polymerase chain reaction market to reach US$ 11,142.2 million by 2030, growing at a compound annual growth rate of 8.9% during the forecast period (2022-2030). Key industry players are actively pursuing inorganic growth strategies, including acquisitions such as Agilent Technologies' $550 million purchase of Resolution Bioscience (March 2021), Thermo Fisher Scientific's acquisition of Mesa Biotech (January 2021), and Labcorp's acquisition of Personal Genome Diagnostics (February 2022), all aimed at expanding capabilities in precision medicine, cancer diagnostics, and genomic profiling. North America holds the largest regional market share, with academic and research laboratories representing the dominant end-user segment.PR NewswireGlobal Precision Medicine Markets, 2016-2020 & 2021-2026ResearchAndMarkets added a market forecast report for the Global Precision Medicine Market, valued at USD 66.85 billion in 2020 and projected to reach USD 125.67 billion by 2026, growing at a CAGR of 10.65%. On April 15, 2021, Agilent Technologies completed the acquisition of Resolution Bioscience to expand its next-generation sequencing-based cancer diagnostics capabilities. Rising cancer cases in developing economies like India and China are cited as key growth drivers, while high pricing of precision medicines is identified as a potential market restraint.PR NewswireGlobal Molecular Diagnostics for Cancer Markets Report 2021-2025: Companion Diagnostics and Liquid Biopsy Drive Market Growth while Lowering Costs; COVID-19 Causes Resources ShiftResearchAndMarkets has published a market forecast report on molecular diagnostics for cancer covering 2021–2025, profiling over 130 companies in the sector. The report identifies key growth drivers including companion diagnostics, liquid biopsy, personalized medicine, and pharmacogenomics, while noting COVID-19 has shifted resources and may interrupt growth in the near term. Recent developments highlighted in the report include multiple acquisitions (Invitae's $200M purchase of Genosity, Agilent's acquisition of Resolution Bioscience), financing rounds (Singlera Genomics' $150M funding), and FDA approvals such as Foundation Medicine's liquid biopsy companion diagnostics.FinSMEsAgilent To Buy Resolution Bioscience, For Up To $695MAgilent Technologies agreed to acquire Resolution Bioscience, a next-generation sequencing precision oncology provider, for up to $695 million. The deal includes $550 million in cash at closing and up to $145 million in milestone payments, expected to close in April. The acquisition aims to expand Agilent's NGS-based cancer diagnostics capabilities.PR NewswireU.S./Australian Study Highlights Rapid Analysis and Clinical Utility of Liquid Biopsy AssayResearchers from Memorial Sloan Kettering Cancer Center, the University of Sydney, and Resolution Bioscience conducted a prospective clinical study demonstrating that Resolution's ctDx Lung liquid biopsy assay can rapidly guide targeted treatment for metastatic non-small cell lung cancer patients. The study showed the blood-based test reduced mean turnaround times to nine days compared to 20 days for tissue biopsies and led to clinical responses in 97 percent of evaluable patients receiving targeted therapy based on its results. These findings contributed to the New York State Department of Health's approval of the ctDx Lung assay for clinical use.PR NewswireResolution Bioscience Earns New York State Approval for Blood-Based Lung Cancer AssayResolution Bioscience has received laboratory permit and regulatory approval from the New York State Clinical Laboratory Evaluation Program (NY CLEP) for its ctDx Lung cancer assay, a next-generation sequencing liquid biopsy test that detects actionable mutations in non-small cell lung cancer from blood samples. The non-invasive test can identify all four mutation types including single nucleotide variations, insertions and deletions, copy number variations, and gene fusions, enabling clinicians to guide treatment decisions and track tumor response over time. The company, founded in 2012 and privately held, stated this certification validates its liquid biopsy technology and will enable it to expand clinical studies and reach more patients in New York State.